[ad_1]
The fight against the virus continues in Lombardy. The numbers, as always, will be given by Pirellone in the afternoon.
Subscribe to MilanoToday YouTube Channel: Free Videos and Trailers
Already 600 volunteers for Lombard vaccine
Almost 600 volunteers have already applied to test the vaccine against the virus that is being developed at the San Gerardo hospital in Monza and developed by Takis and Rottapharm Biotech. Carried out by the ASST Research Center, in collaboration with the University of Milan-Bicocca, the ‘Phase 1’ experimentation in humans will aim to verify the efficacy of a DNA-based vaccine that is also innovative from a clinical point of view. LombardiaNotizieOnline’s in-depth study was dedicated to this topic, which included Paolo Bonfanti, scientific director of the project, director of ‘Infectious Diseases SC’ and associate in infectious diseases at the University Milano-Bicocca; Marina Cazzaniga, director of the San Gerardo Phase 1 Research Center and professor of medical oncology at Bicocca and Mario Alparone, general director of ASST Monza. Human experimentation consists of 3 phases and is the first step towards large-scale use of the vaccine.
The “Phase 1” will last approximately 3 months and after a period of “follow-up” the results will be analyzed. The next ‘Phase 2’ will be attended by 200 people, selected from the 582 who have already presented and registered in the Volunteer Registry and from those who will still be proposed in the coming days.
How to contribute to the study
It is possible to apply to participate as a volunteer in the ‘Phase 1’ experimentation by sending an email to [email protected]. To do this, you must be between 18 and 65 years old and have not come into contact with the virus. You also must not have had hepatitis or HIV. Good general psychophysical conditions are essential.
Prior to vaccine inoculation, volunteers selected for ‘Phase 1’ will undergo a series of clinical tests, based on blood and instrumental tests. They will take place between the end of October and the beginning of November. 14 days after the vaccination, the ASST Monza team researchers will proceed to take blood samples from the subjects involved in the experiment, to extract the antibodies produced by their organisms. These will come into contact with the active virus. If the extracted antibodies neutralize the virus, the vaccine will be successful.
Your browser cannot play the video.
You have to disable ad blocking to play the video.
stain
Can not play video; Try it again later.
Wait a minute...
Maybe you might be interested...
You need to enable javascript to play the video.
The genetic vaccine does not use an inactivated virus that is used as a viral vector to stimulate the production of antibodies. Composed of a DNA fragment, once injected into a healthy subject, it stimulates an immune reaction that is capable of preventing infection.
